Literature Review

PRECISION MEDICINE IN HEPATOBILIARY DISEASE: A CLINICAL REVIEW

Naresh Bansal1*, Ashish Kumar1, Praveen Sharma1, Shreehari Anikhandi1, Shivam Khare1, Anil Arora1

Author information: 1. Department of Gastroenterology and Hepatology, Shri Ganga Ram Hospital, Delhi, India,

Received: 06-19-2024; Accepted: 07-04-2024; Published: 07-10-2024.

Abstract. This review delves into the molecular intricacies of hepatobiliary diseases, emphasizing their genetic and molecular foundations. It explores the expanding scope of precision medicine, advocating for tailored approaches based on individual genomic profiles to enhance diagnostic and therapeutic strategies. The genetic and molecular basis of conditions such as hepatitis and cirrhosis are dissected, revealing specific mutations' roles in susceptibility and disease progression. The narrative underscores precision medicine's potential in steering hepatobiliary medicine toward personalized, effective healthcare models. Overall, advancements in genomic research promise targeted interventions for improved outcomes in managing complex hepatobiliary disorders.

Keywords: Hepatobiliary diseases, Precision medicine, Genetic basis, Non-Alcoholic Fatty Liver Disease (NAFLD), Intrahepatic cholangiocarcinoma.

SCOPE OF PRECISION MEDICINE IN THE CONTEXT OF HEPATOBILIARY DISORDER Precision medicine in the context of hepatobiliary disorders involves tailoring medical approaches to individual patient's unique genetic and molecular characteristics. It encompasses the comprehensive analysis of a patient's genomic profile to identify specific mutations and biomarkers associated with hepatobiliary diseases. This information leads to personalized and targeted diagnostic, treatment, and prevention strategies [3]. This approach allows healthcare professionals to select therapies that specifically target the molecular pathways driving the disease, potentially enhancing treatment efficacy and minimizing adverse effects. Precision medicine in hepatobiliary disorders extends to early detection, prevention, and continuous monitoring of treatment responses based on individual molecular and genetic markers (Figure 1). As our understanding of the molecular basis of diseases advances, the integration of precision medicine holds promise for optimizing patient care in hepatobiliary medicine, moving away from a one-size-fits-all paradigm towards a more tailored and effective healthcare model [2,4].

GENETIC AND MOLECULAR BASIS OF HEPATOBILIARY DISEASES

The genetic and molecular basis of hepatobiliary diseases involves a complex interplay of factors contributing to the initiation, progression, and clinical outcomes of disorders affecting the liver and biliary system [5,6]. In hepatobiliary diseases such as hepatitis, cirrhosis, and liver cancer, genetic factors play a crucial role in susceptibility and disease manifestation [7]. Specific genetic mutations and variations can influence the host response to infections, the progression of fibrosis in chronic liver diseases, and the development of hepatocellular carcinoma [8].

Molecular pathways associated with hepatobiliary diseases encompass a range of cellular processes, including inflammation, apoptosis, angiogenesis, and DNA repair [9]. Dysregulation of these pathways, often triggered by genetic abnormalities or environmental factors, can lead to pathological liver and biliary system changes. For example, chronic inflammation driven by viral infections or autoimmune responses can contribute to liver damage and fibrosis [10].

Genetic predispositions also influence the risk of developing conditions like gallstones, where variations in genes involved in cholesterol metabolism or bile composition can contribute to stone formation. In diseases of the bile ducts, such as primary biliary cirrhosis (PBC) or primary sclerosing cholangitis (PSC), genetic
factors are believed to contribute to immune-mediated damage [11].

Advancements in genomic technologies have facilitated genome-wide association studies (GWAS) and whole-genome sequencing, allowing researchers to identify specific genetic markers associated with hepatobiliary diseases. Understanding these disorders' genetic and molecular basis provides insights into disease etiology. It serves as a foundation for developing targeted therapies and personalized treatment strategies within the emerging field of precision medicine. As our understanding continues to evolve, integrating genetic and molecular information holds promise for improved risk prediction, early detection, and more effective management of hepatobiliary diseases [12,13].

IDENTIFICATION OF KEY MOLECULAR PATHWAYS INVOLVED The intricate molecular pathways in hepatobiliary diseases dictate the progression and outcomes of disorders affecting the liver and biliary system. Chronic inflammation, a common thread in conditions such as viral hepatitis and non-alcoholic fatty liver disease, activates pro-inflammatory cytokines, initiating signaling cascades that contribute to tissue damage and fibrosis [10]. Dysregulation of apoptosis, fibrogenesis pathways, oxidative stress, and angiogenesis further play pivotal roles in diseases like liver cirrhosis and hepatocellular carcinoma [14]. Abnormalities in metabolic pathways, including lipid metabolism and insulin signaling, underlie conditions such as non-alcoholic fatty liver disease. Notch signaling and the Wnt/β-catenin pathway are implicated in cell fate decisions and hepatocellular carcinoma development. Understanding the nuanced interactions within these molecular pathways is essential for unraveling the complex pathophysiology of hepatobiliary diseases, offering insights into potential therapeutic targets, and paving the way for precision medicine approaches tailored to individual molecular profiles [15,16].

CURRENT BIOMARKERS AND DIAGNOSTIC TOOLS USED IN HEPATOBILIARY DIAGNOSIS Biomarkers and diagnostic tools are pivotal in identifying, stratifying, and monitoring hepatobiliary diseases, providing valuable insights for accurate diagnosis and tailored treatment approaches. Biomarkers, measurable indicators in biological samples, are key diagnostic tools to assess disease presence, progression, and response to therapy [17]. In hepatobiliary
diseases, various biomarkers are utilized, as shown in Table 1.

These biomarkers and diagnostic tools collectively contribute to a comprehensive diagnostic approach in hepatobiliary diseases, enabling healthcare professionals to make informed decisions about patient management.

The integration of these tools facilitates early detection, risk stratification, and personalized treatment plans, aligning with the principles of precision medicine and ultimately improving patient outcomes in the complex landscape of hepatobiliary disorders [18].

**EXPLORATION OF NOVEL BIOMARKERS AND DIAGNOSTIC TOOLS ENABLED BY PRECISION MEDICINE** The advent of precision medicine has brought about a transformative era in the exploration of biomarkers and diagnostic tools for hepatobiliary diseases [19]. Genomic profiling, a cornerstone of precision medicine, enables the identification of specific genetic mutations associated with these disorders, laying the groundwork for discovering novel biomarkers indicative of disease risk, progression, and treatment response. Liquid biopsy techniques, analyzing circulating biomarkers in the bloodstream, offer noninvasive opportunities for early detection, monitoring, and characterization of hepatobiliary diseases, providing a real-time assessment of the molecular landscape. Integrating advanced imaging technologies, molecular imaging, and contrast-enhanced techniques with precision medicine principles enhances the accuracy and targeted visualization of liver and bile duct abnormalities [20]. Innovative biomarkers related to immune responses, epigenetic modifications, and metabolomics contribute to a more comprehensive understanding of the molecular signatures associated with hepatobiliary diseases. Moreover, applying artificial intelligence and machine learning to analyze extensive datasets promises to identify novel patterns and associations, enhance diagnostic accuracy, and pave the way for a more personalized

<table>
<thead>
<tr>
<th>S.no.</th>
<th>Biomarkers</th>
<th>Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Liver Enzymes</td>
<td>Elevated levels of liver enzymes such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST) indicate liver damage and are commonly used in liver function tests.</td>
</tr>
<tr>
<td>2</td>
<td>Serological Markers for Viral Hepatitis</td>
<td>Specific antibodies and viral antigens are employed to diagnose and differentiate between different types of viral hepatitis (e.g., Hepatitis B surface antigen - HBsAg).</td>
</tr>
<tr>
<td>3</td>
<td>Alpha-fetoprotein (AFP)</td>
<td>Elevated AFP levels are associated with hepatocellular carcinoma and can be used as a tumor marker for diagnosis and monitoring.</td>
</tr>
<tr>
<td>4</td>
<td>Imaging Techniques</td>
<td>Ultrasonography, CT scans, and MRI are employed for visualizing liver structure, detecting tumors, and assessing the extent of fibrosis or cirrhosis.</td>
</tr>
<tr>
<td>5</td>
<td>Fibrosis Markers</td>
<td>Non-invasive markers like FibroTest and elastography assess liver fibrosis without the need for a liver biopsy.</td>
</tr>
<tr>
<td>6</td>
<td>Bile Duct Imaging</td>
<td>Imaging modalities like MRCP (Magnetic Resonance Cholangiopancreatography) and ERCP (Endoscopic Retrograde Cholangiopancreatography) aid in visualizing the biliary system and detecting disorders like bile duct stones or strictures.</td>
</tr>
<tr>
<td>7</td>
<td>Genomic Profiling</td>
<td>Advances in genetic testing allow for the identification of specific genetic mutations associated with hepatobiliary diseases, aiding in risk assessment and personalized treatment decisions.</td>
</tr>
<tr>
<td>8</td>
<td>Liquid Biopsy</td>
<td>Emerging as a non-invasive tool, liquid biopsy involves analyzing circulating biomarkers (such as cell-free DNA) in blood for early cancer detection and monitoring treatment response.</td>
</tr>
</tbody>
</table>

**Table 1. Showing the various Biomarkers with their diagnosis.**
healthcare model. As precision medicine evolves, the collaborative effort across disciplines continues to propel the development and integration of these advancements into clinical practice, promising a revolutionary impact on the early detection, diagnosis, and management of hepatobiliary diseases and ultimately improving patient outcomes through tailored interventions [21,22].

**PERSONALIZED TREATMENT APPROACHES** Personalized treatment approaches in hepatobiliary diseases represent a transformative shift in healthcare driven by the principles of precision medicine. These approaches involve tailoring therapeutic interventions to the individual characteristics of patients, including their genetic makeup, molecular profiles, and specific disease manifestations [23]. In hepatobiliary diseases, personalized treatment strategies aim to optimize efficacy while minimizing adverse effects. The main aspects of personalized treatment approaches include:

**Targeted Therapies**: Identification of specific genetic mutations or molecular abnormalities associated with the disease allows for the development and utilization of targeted therapies. For example, drugs like sorafenib and regorafenib in hepatocellular carcinoma target specific pathways involved in tumor growth.

**Immunotherapy**: Harnessing the patient’s immune system to combat hepatobiliary cancers is an emerging personalized approach. Immune checkpoint inhibitors, such as nivolumab and pembrolizumab, show promise in certain cases of advanced liver cancer.

**Individualized Chemotherapy**: Tailoring chemotherapy regimens based on the genetic and molecular characteristics of the tumor helps optimize treatment responses and minimize side effects. This approach is particularly relevant in cholangiocarcinoma and certain types of liver cancer [24].

**Genomic Profiling for Drug Selection**: Genetic testing can guide the selection of medications that are more likely to be effective and less toxic for the individual patient. Understanding the genetic basis of drug metabolism can influence dosing and drug choices.

**Risk Stratification**: Precision medicine allows for the identification of patients at higher risk for disease progression or recurrence. This information helps guide treatment decisions, including the intensity and duration of therapy.

**Combination Therapies**: Rational combinations of drugs targeting different pathways may be employed based on the patient’s unique molecular profile. This approach aims to enhance treatment efficacy by simultaneously addressing multiple aspects of the disease.

**Monitoring Treatment Response**: Personalized approaches include regular monitoring of treatment responses using biomarkers, imaging, and other diagnostic tools. Based on real-time data, adjustments to the treatment plan can be made, ensuring ongoing effectiveness [3,25]. While personalized treatment approaches hold great promise, challenges remain, including the need for more comprehensive biomarker panels, standardized protocols for genomic profiling, and broader access to advanced therapies (Figure 2). Nonetheless, as the field of precision medicine continues to advance, personalized treatment strategies for hepatobiliary diseases are expected to play an increasingly pivotal role in improving patient outcomes and quality of life [2,26].

**OVERVIEW OF TARGETED THERAPIES BASED ON MOLECULAR PROFILES** Targeted therapies based on molecular profiles have revolutionized the treatment landscape for hepatobiliary diseases, offering more precise and effective interventions by directly addressing specific molecular and genetic aberrations associated with these conditions. This approach represents a paradigm shift from traditional, non-specific treatments, providing a more personalized and targeted strategy. Here is an overview of targeted therapies in hepatobiliary diseases: These targeted therapies aim to disrupt specific molecular pathways that drive the growth and survival of cancer cells or contribute to the pathogenesis of hepatobiliary diseases [27,28]. While targeted therapies often show promising results, challenges include the potential development of resistance, side effects, and the need for ongoing research to refine treatment strategies (Table 2). Integrating molecular profiling into clinical decision-making is critical for identifying patients most likely to benefit from these targeted therapies, marking a significant advancement toward more personalized and effective treatment approaches in hepatobiliary diseases.

**GENOMIC PROFILING IN HEPATOBILIARY DISEASE**

In hepatobiliary diseases, genomic profiling is a comprehensive tool for dissecting the genetic landscape of tumor cells or tissues, offering valuable insights into the specific mutations, alterations, and molecular pathways underlying disease development and progression. At its
core, genomic profiling enables the identification of driver mutations, such as those in TP53, CTNNB1, and KRAS, which actively contributes to cancer formation. Beyond mere identification, this approach allows the stratification of patients into distinct subgroups based on their unique molecular profiles, providing a foundation for personalized treatment decisions and predicting responses to targeted therapies. Moreover, genomic profiling furnishes prognostic information, guiding clinicians in tailoring treatment intensity and follow-up strategies based on the anticipated course and outcomes of the disease. This method plays a pivotal role in developing and selecting targeted therapies aligned with individual tumor biology by uncovering therapeutic targets and potential vulnerabilities. Serial genomic profiling further facilitates the dynamic monitoring of genetic changes over time, offering insights into disease evolution and the emergence of resistance mechanisms. Crucially, this approach integrates seamlessly with liquid biopsy, providing a minimally invasive means of monitoring molecular changes and detecting tumor-specific alterations. As an integral facet of precision medicine, genomic profiling shapes and advances our approach to hepatobiliary diseases, promising increasingly tailored and effective therapeutic strategies as technological advancements persist [29,30].

EMERGING TECHNOLOGIES AND TRENDS IN PRECISION MEDICINE FOR HEPATOBILIARY DISORDERS

Advances in genomic sequencing technologies have transformed our ability to decode individuals' genetic information, contributing significantly to precision medicine and our understanding of complex diseases, including hepatobiliary disorders. Several key advancements have propelled genomic sequencing technologies forward:

**Next-Generation Sequencing (NGS):** NGS technologies have revolutionized genomic sequencing by enabling the parallel analysis of millions of DNA fragments. This high-throughput approach has drastically reduced the cost and time required for sequencing, making genomic information more accessible [31].
Whole Genome Sequencing (WGS): WGS involves sequencing an individual's entire genome, providing a comprehensive view of their genetic makeup. While initially resource-intensive, technological advancements have made WGS more cost-effective and feasible for large-scale studies.

Whole Exome Sequencing (WES): WES selectively sequences the genome's protein-coding regions, known as the exome. This focused approach allows for the identification of coding mutations, which are often critical in the context of disease and are more cost-effective than WGS [32].

<table>
<thead>
<tr>
<th>S.no.</th>
<th>Molecular Profile</th>
<th>Drug</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Hepatocellular Carcinoma</td>
<td>Sorafenib</td>
<td>A tyrosine kinase inhibitor targeting multiple pathways involved in angiogenesis and tumor cell proliferation. Extends the inhibition of tyrosine kinases, offering an option for patients who progress on sorafenib. Another multi-kinase inhibitor with anti-angiogenic effect(s used for advanced HCC.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Regorafenib</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lenvatinib</td>
<td></td>
</tr>
<tr>
<td>2.</td>
<td>Cholangiocarcinoma</td>
<td>IDH Inhibitors(e.g., Ivosidenib, Enasidenib)</td>
<td>Target mutated isocitrate dehydrogenase enzymes found in a subset of cholangiocarcinomas Target fibroblast growth factor receptor mutations or fusions.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FGFR Inhibitors (e.g., Pemigatinib)</td>
<td></td>
</tr>
<tr>
<td>3.</td>
<td>Colorectal Liver Metastases:</td>
<td>Anti-EGFR Antibodies (e.g., Cetuximab, Panitumumab)</td>
<td>Target epidermal growth factor receptor overexpression in colorectal cancer cells. Inhibit vascular endothelial growth factor, suppressing angiogenesis.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anti-VEGF Antibodies (e.g., Bevacizumab)</td>
<td></td>
</tr>
<tr>
<td>4.</td>
<td>Primary Biliary Cholangitis (PBC)</td>
<td>Obeticholic Acid</td>
<td>A farnesoid X receptor agonist that regulates bile acid synthesis, approved for PBC treatment.</td>
</tr>
<tr>
<td>5.</td>
<td>Primary Sclerosing Cholangitis (PSC)</td>
<td></td>
<td>No specific targeted therapies have been approved yet, but ongoing research is exploring potential targets.</td>
</tr>
<tr>
<td>6.</td>
<td>Genetic and Molecular Profiling</td>
<td></td>
<td>Comprehensive genomic profiling helps identify specific mutations or alterations in individual patients, guiding the selection of targeted therapies based on their unique molecular profiles</td>
</tr>
</tbody>
</table>

Table 2. Showing the targeted therapies based on molecular profiles.
Single-Cell Sequencing: Single-cell sequencing technologies enable the analysis of individual cells, allowing for the identification of cellular heterogeneity within tissues. This is particularly relevant in understanding tumor heterogeneity in hepatobiliary cancers and identifying rare cell populations [33].

Long-Read Sequencing: Long-read sequencing technologies, such as PacBio and Oxford Nanopore, produce longer DNA sequences, overcoming challenges associated with repetitive regions of the genome. This is crucial for accurately identifying structural variations and complex genomic rearrangements.

Liquid Biopsy: Liquid biopsy is a noninvasive technique that involves sequencing cell-free DNA circulating in the bloodstream. This approach is particularly useful for monitoring tumor dynamics, detecting minimal residual disease, and assessing treatment responses in hepatobiliary cancers.

CRISPR: CRISPR-based genome editing enables precise interventions by validating the functional significance of identified genetic alterations.

Integration of Multi-Omics Data: Integrating genomics with other 'omics' data, such as transcriptomics, proteomics, and metabolomics, provides a holistic understanding of biological processes. This multi-omics approach enhances our ability to unravel the complexities of hepatobiliary diseases.

Artificial Intelligence and Machine Learning: AI and machine learning applications are being integrated with genomic data analysis, aiding in interpreting vast datasets. These technologies assist in identifying patterns, predicting disease risk, and refining personalized treatment strategies based on genomic information. These advances collectively empower researchers and clinicians to delve deeper into the molecular underpinnings of hepatobiliary diseases. The evolving landscape of genomic sequencing technologies continues to enhance our ability to unravel the intracacies of the genome, paving the way for more targeted and personalized approaches in the diagnosis and treatment of hepatobiliary disorders [2,34].

CHALLENGES AND STRATEGIES IN PRECISION MEDICINE FOR HEPATOBILIARY DISEASES Implementing precision medicine in hepatobiliary diseases confronts intricate challenges, mirroring the dynamic nature of these conditions. Key obstacles include the inherent tumor heterogeneity within hepatobiliary tumors, presenting diverse genetic profiles across regions, and complicating the identification of targetable mutations. Additionally, the limited availability of FDA-approved therapies for specific genomic alterations restricts precision medicine's broader applicability [35,36]. Standardized guidelines for genomic testing, interpretation, and treatment decision-making need to be improved, adding complexity and emphasizing the need for consensus frameworks to integrate precision medicine seamlessly into clinical practice. Access to advanced genomic profiling technologies, especially in resource-constrained settings, raises concerns about potential disparities in adoption [37].

Ethical and legal considerations, including informed consent, patient privacy, and genetic discrimination, must be addressed to ensure responsible use of genomic information. Overcoming these challenges requires concerted efforts to integrate genomic data into clinical workflows, reduce testing costs, bridge educational gaps, design clinical trials incorporating genomic information, and develop robust data integration and analysis infrastructure.

Long-term monitoring and adaptation of treatment strategies based on evolving genomic profiles underscore the necessity for effective systems and continuous patient follow-up. Overcoming these challenges demands a collaborative, multidisciplinary approach involving researchers, clinicians, policymakers, and industry stakeholders, alongside ongoing research and technological advancements, to unlock the full potential of precision medicine in hepatobiliary diseases. In addressing limitations, a comprehensive strategy is imperative. Initiatives should focus on expanding access to genomic profiling, advocating for financial support, and reducing testing costs, particularly in resource-constrained regions. Establishing standardized guidelines and protocols for genomic testing and interpretation through collaboration between healthcare organizations and regulatory bodies is crucial. Research and development efforts should intensify to broaden the spectrum of targeted therapies. Educational programs must enhance the genomic literacy of healthcare professionals, and robust ethical and legal frameworks are essential for transparent communication. Improving bioinformatics infrastructure, encouraging data-sharing initiatives, and incorporating patient perspectives into decision-making are vital for effective genomic information integration. Interdisciplinary
collaboration among clinicians, geneticists, and bioinformaticians, supported by multidisciplinary tumor boards, is crucial. Strategies for long-term patient monitoring and developing continuous adaptation systems based on evolving genomic profiles are crucial, prioritizing health equity to address disparities in access. Encouraging innovative clinical trial designs, streamlining regulatory processes and investing in ongoing research and development are key components of an effective strategy to advance precision medicine in hepatobiliary diseases, delivering more personalized and effective care for individuals with these conditions.

**SPECIFIC CASES WHERE PRECISION MEDICINE HAS SHOWN PROMISING RESULTS** Precision medicine has demonstrated significant success in various instances within the realm of hepatobiliary diseases. It is crucial to emphasize that our comprehension of the effectiveness of precision medicine is continually evolving through ongoing research and clinical trials. Here, we highlight a few instances where precision medicine has yielded noteworthy results:

**Targeting FGFR Alterations in Cholangiocarcinoma:** Intrahepatic cholangiocarcinoma (iCCA) often harbors genetic alterations in the FGFR (fibroblast growth factor receptor) pathway. Clinical trials, such as the FIGHT-202 trial, have investigated FGFR inhibitors like pemigatinib in patients with advanced cholangiocarcinoma with FGFR2 fusions or rearrangements. Positive results from these trials have led to the FDA approval of pemigatinib for this specific genomic subgroup, highlighting the success of precision medicine in addressing a distinct molecular subtype [38].

**IDH Inhibitors in Cholangiocarcinoma and HCC:** Isocitrate dehydrogenase (IDH) mutations are found in a subset of cholangiocarcinomas and hepatocellular carcinomas (HCC). Clinical trials, such as the ClarIDHy trial for ivosidenib and the AGILE trial for enasidenib, demonstrated efficacy in treating cholangiocarcinoma with IDH mutations. Additionally, these IDH inhibitors are being explored in HCC cases with IDH mutations, showcasing the potential of precision medicine in targeting specific genetic alterations across different hepatobiliary cancers [39].

**Immunotherapy in Hepatocellular Carcinoma (HCC):** Checkpoint inhibitors, such as nivolumab and pembrolizumab, have shown promising results in treating advanced HCC. Precision medicine approaches involve identifying patients with specific biomarkers, such as high levels of programmed death-ligand 1 (PD-L1) expression, to predict better responses to immunotherapy. The KEYNOTE-240 trial demonstrated improved overall survival in patients with advanced HCC treated with pembrolizumab [40].

**EGFR-Targeted Therapies in Colorectal Liver Metastases:** Precision medicine plays a role in selecting targeted therapies for colorectal cancer with specific genomic alterations. Patients with wild-type RAS and BRAF mutations may benefit from anti-EGFR therapies like cetuximab or panitumumab. Genetic testing informs treatment decisions, ensuring that patients most likely to respond to these therapies receive them, showcasing the impact of precision medicine in colorectal liver metastases [40].

**BRAF V600E Mutation-Driven Therapy in Hepatocellular Carcinoma:** Precision medicine has proven effective in hepatocellular carcinoma (HCC) cases marked by the BRAF V600E mutation. Targeted therapies, including vemurafenib, originally developed for melanoma, have shown efficacy in a subgroup of HCC patients with this mutation. Genomic profiling aids in identifying such mutations, enabling tailored treatment strategies for enhanced efficacy [41].

**Targeting NTRK Fusions in Biliary Tract Cancers:** Precision medicine has successfully treated biliary tract cancers exhibiting neurotrophic receptor tyrosine kinase (NTRK) fusions. Specific inhibitors like larotrectinib and entrectinib, designed to target NTRK fusions, have demonstrated positive outcomes. Genomic profiling is instrumental in identifying these fusions, allowing targeted therapies and improved treatment responses in this subset of patients [42].

**Immunotherapy for MSI-H Hepatobiliary Cancers:** Precision medicine has shown promise in hepatobiliary cancers with microsatellite instability-high (MSI-H) status. Immunotherapy, specifically immune checkpoint inhibitors like pembrolizumab, has displayed encouraging results in MSI-H tumors. Genomic profiling plays a critical role in identifying MSI-H status and guiding the application of immunotherapy as an effective treatment option for eligible patients [43].

**IMPACT OF PERSONALIZED APPROACHES ON PATIENT OUTCOMES** Personalized approaches in healthcare, particularly exemplified by precision medicine, have exerted profound positive effects on patient outcomes in
various medical conditions, including hepatobiliary diseases. A striking instance is the enhanced treatment efficacy achieved through tailored therapies guided by genomic profiling. In hepatocellular carcinoma, for instance, the utilization of targeted therapies like sorafenib or lenvatinib, tailored to an individual's genomic profile, has led to heightened response rates and prolonged survival. The personalized consideration of individual variations in drug metabolism and response contributes to a notable reduction in adverse effects, optimizing the selection of therapies for greater efficacy and improved quality of life. Precision medicine's capacity to identify specific genetic mutations or molecular markers empowers clinicians to select treatments precisely targeting the root cause of the disease, resulting in more effective and timely interventions that positively impact patient outcomes. Early detection and prevention efforts, including genetic testing for hereditary liver diseases, enable proactive measures and interventions, exemplified by identifying individuals at risk for hereditary hemochromatosis. Precision medicine further informs individualized surveillance strategies, allowing for early detection of potential issues, timely interventions, and an overall improved prognosis. Genomic profiling's contribution to prognostication aids in risk stratification, striking a balance between aggressive treatment and maintaining a high quality of life. Participation in clinical trials targeting specific genomic alterations provides patients with access to innovative treatments and contributes to advancing medical knowledge to benefit future patients. Additionally, personalized medicine fosters patient empowerment by encouraging active engagement in decision-making processes, instilling a sense of control over their healthcare journey. While the positive impact of personalized approaches on patient outcomes is increasingly evident, recognizing existing challenges and limitations underscores the ongoing need for continuous research, technological advancements, and collaborative efforts to refine and expand the benefits of personalized approaches in hepatobiliary diseases and beyond [44].

**POtential Areas for Further Research and Development** The evolution of precision medicine for hepatobiliary disorders hinges on targeted research and development in key areas. Identifying and validating novel biomarkers across various bodily fluids is crucial for early detection and treatment monitoring. Functional genomics studies will unravel the functional consequences of genetic alterations, guiding the development of targeted therapies. Investigating the tumor microenvironment's role in hepatobiliary cancers and understanding therapeutic resistance mechanisms is imperative for uncovering new treatment opportunities. Population-based genomic studies can unveil population-specific genetic variations, allowing tailored precision medicine approaches.

Further integrating multi-omics data and refining patient stratification strategies based on comprehensive genomic profiling will enhance treatment precision. Improving clinical trial design with robust biomarker development, enhancing genetic counseling, integrating health information technology, and expanding research into pediatric hepatobiliary diseases are essential steps. Global collaborations for data sharing, health economics studies, and assessing patient-reported outcomes will collectively advance precision medicine, fostering innovations and improving the understanding, diagnosis, and treatment of hepatobiliary disorders. Collaborative efforts among stakeholders will be paramount for successfully advancing these critical research areas [45].

**Ethical Implications of Precision Medicine in Hepatobiliary Diseases** The ethical dimensions surrounding precision medicine in hepatobiliary diseases demand careful consideration across various crucial aspects. Obtaining informed consent from patients undergoing genomic testing is a fundamental ethical principle, ensuring autonomy by transparently communicating the testing process's purpose, risks, and benefits. The sensitivity of genomic data requires robust measures to safeguard privacy and confidentiality, fostering patient trust in the responsible handling of their genetic information. Addressing disparities in access to precision medicine interventions is an ethical imperative, promoting equitable healthcare delivery. The return of genomic results necessitates clear guidelines to determine clinical significance and thoughtful communication with patients, acknowledging the potential psychosocial impact. Ethical considerations extend to pediatric genomic testing, emphasizing the delicate balance between potential benefits and respecting the evolving autonomy of the child. Community engagement, transparency in research, and ongoing education contribute to the ethical foundation of precision medicine in hepatobiliary diseases. Ultimately, navigating these ethical considerations ensures a responsible and patient-centric approach, upholding the core principles of beneficence, autonomy, justice, and non-maleficence to pursue improved healthcare outcomes [46].
CONCLUSION In conclusion, the advent of precision medicine represents a transformative breakthrough in managing hepatobiliary diseases, ushering in an era marked by personalized diagnostics, targeted therapies, and enhanced patient outcomes. However, this innovative paradigm is accompanied by a complex web of ethical considerations that necessitate meticulous attention to ensure the responsible and equitable utilization of genomic information. Paramount among these ethical concerns is the need to safeguard patient privacy, demanding robust security measures and well-defined guidelines to protect the sensitivity of genomic data. Informed consent emerges as a foundational principle, requiring comprehensive patient education and adaptable models to navigate the dynamic landscape of genomic research. Transparent communication regarding the return of results becomes pivotal in empowering patients with meaningful information. The ethical imperative of equity resonates strongly, advocating for eliminating disparities in accessing precision medicine, promoting inclusivity in research, and ensuring that the benefits reach diverse populations. The landscape of pediatric genomic testing introduces unique challenges, demanding a delicate balance between obtaining assent and consent, considering long-term implications, and providing essential psychosocial support for both children and their families. As the future of precision medicine unfolds with emerging technologies and evolving research avenues, the unwavering emphasis on ethical frameworks remains crucial. Collaboration among healthcare professionals, researchers, policymakers, and patients becomes the linchpin in shaping an ethical landscape that fosters trust, addresses societal concerns, and maximizes the potential of precision medicine to offer a more personalized and effective care paradigm for individuals grappling with hepatobiliary disorders.

Conflicts of interest
All authors declare that there are no conflicts of interest.

REFERENCES


38. Aitcheson G, Mahipal A, John BV. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the


